155 related articles for article (PubMed ID: 37951788)
1. Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis.
Maher RE; Barry PJ; Emmott E; Jones AM; Lin L; McNamara PS; Smith JA; Lord RW
J Cyst Fibros; 2024 Mar; 23(2):269-277. PubMed ID: 37951788
[TBL] [Abstract][Full Text] [Related]
2. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW; Murphy J; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD010966. PubMed ID: 33331662
[TBL] [Abstract][Full Text] [Related]
3. Persistence and evolution of
Armbruster CR; Hilliam YK; Zemke AC; Atteih S; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Lee SE; Cooper VS; Bomberger JM
mBio; 2024 May; 15(5):e0051924. PubMed ID: 38564694
[TBL] [Abstract][Full Text] [Related]
4. Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.
Burgel PR; Paillasseur JL; Durieu I; Reynaud-Gaubert M; Hamidfar R; Murris-Espin M; Danner-Boucher I; Chiron R; Leroy S; Douvry B; Grenet D; Mely L; Ramel S; Montcouquiol S; Burnet E; Ouaalaya EH; Sogni P; Da Silva J; Martin C;
Ann Am Thorac Soc; 2024 Jul; 21(7):1053-1064. PubMed ID: 38579175
[No Abstract] [Full Text] [Related]
5. Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey.
Çobanoğlu N; Özçelik U; Çakır E; Şişmanlar Eyüboğlu T; Pekcan S; Cinel G; Yalçın E; Kiper N; Emiralioğlu N; Şen V; Şen HS; Ercan Ö; Çokuğraş H; Kılınç AA; Al Shadfan LM; Yazan H; Altıntaş DU; Karagöz D; Demir E; Kartal Öztürk G; Bingöl A; Başaran AE; Sapan N; Çekiç Ş; Çelebioğlu E; Aslan AT; Gürsoy TR; Tuğcu G; Özdemir A; Harmancı K; Yıldırım GK; Köse M; Hangül M; Tamay Z; Süleyman A; Yüksel H; Yılmaz Ö; Özcan G; Topal E; Can D; Korkmaz Ekren P; Çaltepe G; Kılıç M; Özdoğan Ş; Doğru D
Pediatr Pulmonol; 2020 Sep; 55(9):2302-2306. PubMed ID: 32453906
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Improvement of Cystic Fibrosis Transmembrane Conductance Regulator Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis.
Loske J; Völler M; Lukassen S; Stahl M; Thürmann L; Seegebarth A; Röhmel J; Wisniewski S; Messingschlager M; Lorenz S; Klages S; Eils R; Lehmann I; Mall MA; Graeber SY; Trump S
Am J Respir Crit Care Med; 2024 Jun; 209(11):1338-1350. PubMed ID: 38259174
[No Abstract] [Full Text] [Related]
7. Triple Therapy for Cystic Fibrosis
Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
[TBL] [Abstract][Full Text] [Related]
8. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial.
Nichols DP; Paynter AC; Heltshe SL; Donaldson SH; Frederick CA; Freedman SD; Gelfond D; Hoffman LR; Kelly A; Narkewicz MR; Pittman JE; Ratjen F; Rosenfeld M; Sagel SD; Schwarzenberg SJ; Singh PK; Solomon GM; Stalvey MS; Clancy JP; Kirby S; Van Dalfsen JM; Kloster MH; Rowe SM;
Am J Respir Crit Care Med; 2022 Mar; 205(5):529-539. PubMed ID: 34784492
[No Abstract] [Full Text] [Related]
9. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
10. Sex differences in outcomes of people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor.
Wang A; Lee M; Keller A; Jian S; Lowe K; Finklea JD; Jain R
J Cyst Fibros; 2024 Jan; 23(1):91-98. PubMed ID: 37244841
[TBL] [Abstract][Full Text] [Related]
11. Lung clearance index (LCI
Urquhart DS; Dowle H; Moffat K; Forster J; Cunningham S; Macleod KA
Pediatr Pulmonol; 2024 May; 59(5):1449-1453. PubMed ID: 38415920
[TBL] [Abstract][Full Text] [Related]
12. Effect of CFTR modulator therapy with elexacaftor/tezacaftor/ivacaftor on pulmonary ventilation derived by 3D phase-resolved functional lung MRI in cystic fibrosis patients.
Klimeš F; Voskrebenzev A; Gutberlet M; Speth M; Grimm R; Dohna M; Hansen G; Wacker F; Renz DM; Dittrich AM; Vogel-Claussen J
Eur Radiol; 2024 Jan; 34(1):80-89. PubMed ID: 37548691
[TBL] [Abstract][Full Text] [Related]
13. VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Davies JC; Moskowitz SM; Brown C; Horsley A; Mall MA; McKone EF; Plant BJ; Prais D; Ramsey BW; Taylor-Cousar JL; Tullis E; Uluer A; McKee CM; Robertson S; Shilling RA; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Rowe SM;
N Engl J Med; 2018 Oct; 379(17):1599-1611. PubMed ID: 30334693
[TBL] [Abstract][Full Text] [Related]
14. CFTR modulator use in post lung transplant recipients.
Benninger LA; Trillo C; Lascano J
J Heart Lung Transplant; 2021 Dec; 40(12):1498-1501. PubMed ID: 34538541
[TBL] [Abstract][Full Text] [Related]
15. Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor.
Duong JT; Pope CE; Hayden HS; Miller C; Salipante SJ; Rowe SM; Solomon GM; Nichols D; Hoffman LR; Narkewicz MR; Green N
J Cyst Fibros; 2024 May; 23(3):490-498. PubMed ID: 38448281
[TBL] [Abstract][Full Text] [Related]
16. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
Middleton PG; Mall MA; Dřevínek P; Lands LC; McKone EF; Polineni D; Ramsey BW; Taylor-Cousar JL; Tullis E; Vermeulen F; Marigowda G; McKee CM; Moskowitz SM; Nair N; Savage J; Simard C; Tian S; Waltz D; Xuan F; Rowe SM; Jain R;
N Engl J Med; 2019 Nov; 381(19):1809-1819. PubMed ID: 31697873
[TBL] [Abstract][Full Text] [Related]
17. Predicting weight gain in patients with cystic fibrosis on triple combination modulator.
Stewart KL; Szczesniak R; Liou TG
Pediatr Pulmonol; 2024 Jun; 59(6):1724-1730. PubMed ID: 38607242
[TBL] [Abstract][Full Text] [Related]
18. Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis.
Donaldson SH; Corcoran TE; Pilewski JM; Mogayzel P; Laube BL; Boitet ER; Harris ES; Ceppe A; Edwards LJ; Zeman K; Wu J; Esther CR; Nichols DP; Bennett WD; Rowe SM
J Cyst Fibros; 2024 Jan; 23(1):155-160. PubMed ID: 37845149
[TBL] [Abstract][Full Text] [Related]
19. Stepwise Introduction of Elexacaftor-Tezacaftor-Ivacaftor in Patients With Cystic Fibrosis and Liver Cirrhosis Child-Pugh A or B Using Clinical and Therapeutic Drug Monitoring: A Case Series.
Vonk SEM; Lub R; Weersink EJM; Beuers U; Mathôt RAA; Kemper EM; Altenburg J;
Clin Ther; 2024 Feb; 46(2):154-158. PubMed ID: 38042631
[TBL] [Abstract][Full Text] [Related]
20. Patient perspectives on elexacaftor/tezacaftor/ivacaftor after lung transplant.
Young D; Bartlett LE; Guimbellot J; Milinic T; Burdis N; Gill ER; Lease ED; Goss CH; Kapnadak SG; Ramos KJ
J Cyst Fibros; 2024 May; 23(3):545-548. PubMed ID: 37798159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]